Eli Lilly says its weight loss drug Zepbound outperformed Wegovy in a study
Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head randomized controlled trial.
Eli Lilly claims superiority of its weight-loss drug Zepbound after clinical trial
Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative areas of the pharmaceutical indus
Which Weight-Loss Drug Is Better: Wegovy or Zepbound?
W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more effective? In a press release, Lilly announced that in its la
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market.
Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.
Zepbound Tops Wegovy for Weight Loss in Eli Lilly Study
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nor
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.
Eli Lilly’s Weight-Loss Drug Zepbound More Effective than Novo’s Wegovy, Study Shows
Eli Lilly’s obesity drug Zepbound is more effective than rival Novo Nordisk’s drug Wegovy, a head-to-head trial showed, Lilly said in a statement Wednesday. On average, Zepbound led to a superior weight loss of 20.
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.
Lilly's Zepbound Beats Wegovy in Weight-Loss Drug Trial
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters. In the study sponsored by Lilly, those on Zepbound lost an average of about 50 pounds over 72 weeks.
Eli Lilly says Zepbound’s weight-loss results beat those of rival Wegovy
Eli Lilly & Co. Inc.’s stock rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound achieved an average weight loss of 20.
STAT14m
‘Leptin’s last chance’: Mouse study says infamous weight loss drug failure could boost GLP-1s
Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...
Altimmune CEO on what’s next for its experimental obesity drug
Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, ...
Biden Administration Proposes Covering Obesity Drugs In Medicare And Medicaid
It's uncertain whether the Biden administration proposal to cover obesity drugs in Medicare and Medicaid will survive ...
What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Lilly's tirzepatide challenges semaglutide in obesity drug market
The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...
Health on MSN5d
Biden Says Medicare, Medicaid Should Cover Obesity Drugs—What Could That Mean for Access?
The Biden Administration released plans for a new rule that would require Medicare and Medicaid to cover anti-obesity ...
Even with access to blockbuster obesity drugs, some people don't lose weight
Several obesity experts said perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications.
MarketWatch1d
Health Care Flat on Mixed Obesity-Drug Fortunes - Health Care Roundup
Recent data from an Amgen obesity-drug trial only reinforced investors' impressions that Eli Lilly and Novo Nordisk have a prohibitive head start, thanks, in particular, to a new generation of ...